Related references
Note: Only part of the references are listed.Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial
Maurie Markman et al.
GYNECOLOGIC ONCOLOGY (2009)
Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
Jorn Herrstedt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
Michael A. Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
Noriyuki Katsumata et al.
LANCET (2009)
Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial
S. Pignata et al.
ONCOLOGY (2009)
Impact of vessel maturation on antiangiogenic therapy in ovarian cancer
Chunhua Lu et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2008)
Pharmaceutical management of ovarian cancer - Current status
Maurie Markman
DRUGS (2008)
Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer
Chandra P. Belani et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Weekly paclitaxel in the adjuvant treatment of breast cancer
Joseph A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma
Chunhua Lu et al.
CLINICAL CANCER RESEARCH (2007)
A phase 1 study of MORAb-009, a monoclonal antibody against mesothelin in pancreatic cancer, mesothelioma and ovarian adenocarcinoma
D. K. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer
Kirsi A. Suhonen et al.
EUROPEAN JOURNAL OF CANCER (2007)
Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: A Gynecologic Oncology Group study
Lari B. Wenzel et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial
J. -M. Ferrero et al.
ANNALS OF ONCOLOGY (2007)
Intraperitoneal chemotherapy and the NCI clinical announcement
Edward L. Trimble et al.
GYNECOLOGIC ONCOLOGY (2006)
The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR
J. Pfisterer et al.
ANNALS OF ONCOLOGY (2006)
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial
Sandro Pignata et al.
BMC CANCER (2006)
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:: A Gynecologic Oncology Group study
Maurie Markman et al.
GYNECOLOGIC ONCOLOGY (2006)
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
A du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer
A Psyrri et al.
CLINICAL CANCER RESEARCH (2005)
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study
AN Gordon et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer
SE Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic oncology group study
RJ Schilder et al.
CLINICAL CANCER RESEARCH (2005)
Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma
MR Raspollini et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2005)
Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125:: Immunological response and survival (Phase Ib/II)
S Reinartz et al.
CLINICAL CANCER RESEARCH (2004)
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
AN Gordon et al.
GYNECOLOGIC ONCOLOGY (2004)
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
PA Vasey et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
A du Bois et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients
A Romanini et al.
GYNECOLOGIC ONCOLOGY (2003)
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors
T Taniguchi et al.
NATURE MEDICINE (2003)
Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: Results from an intergroup phase II trial
ML Rothenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
PG Rose et al.
GYNECOLOGIC ONCOLOGY (2003)
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells
Ö Alper et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma
I Skirnisdóttir et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2001)
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
PA Vasey et al.
BRITISH JOURNAL OF CANCER (2001)
Intraperitoneal drug delivery of antineoplastics
M Markman
DRUGS (2001)
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
MJ Piccart et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study
FM Muggia et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
